p-Tau217 Adaptive Dosing Protocol

Rank: 19 | Score: 80/100

Overview

[p-Tau217](/biomarkers/p-tau-217) Adaptive Dosing Protocol is a biomarker-guided therapeutic strategy that uses longitudinal p-tau217 (phosphorylated [tau](/proteins/tau) at threonine 217) measurements to dynamically titrate anti-tau immunotherapy dosing. This approach addresses a critical challenge in tau-targeted therapies: the need for personalized dosing based on individual pathological burden and treatment response["@palmqvist2021"][@janelidze2021].

Biological Background

p-Tau217 as a Biomarker

Phosphorylated tau at threonine 217 (p-tau217) has emerged as one of the most promising fluid biomarkers for Alzheimer's disease:

Rank: 19 | Score: 80/100

Overview

[p-Tau217](/biomarkers/p-tau-217) Adaptive Dosing Protocol is a biomarker-guided therapeutic strategy that uses longitudinal p-tau217 (phosphorylated [tau](/proteins/tau) at threonine 217) measurements to dynamically titrate anti-tau immunotherapy dosing. This approach addresses a critical challenge in tau-targeted therapies: the need for personalized dosing based on individual pathological burden and treatment response["@palmqvist2021"][@janelidze2021].

Biological Background

p-Tau217 as a Biomarker

Phosphorylated tau at threonine 217 (p-tau217) has emerged as one of the most promising fluid biomarkers for Alzheimer's disease:

• Specificity: p-tau217 shows high specificity for Alzheimer's disease compared to other neurodegenerative conditions[@palmqvist2021]
• Sensitivity: Detectable in cerebrospinal fluid (CSF) and plasma years before clinical symptoms
• Correlation: Strong correlation with cortical tau burden as measured by PET[@janelidze2021]
• Dynamic range: Levels change in response to disease progression and therapeutic intervention

Rationale for Adaptive Dosing

Current anti-tau immunotherapy approaches use fixed dosing schedules that fail to account for:

• Individual variation in tau pathology burden
• Differential response rates to treatment
• Potential for overtreatment in early-stage patients
• Undertreatment in rapid progressors

• Efficacy: Maintain therapeutic benefit while avoiding underdosing
• Safety: Minimize dose-related adverse events
• Cost: Reduce unnecessary drug exposure
• Precision: Enable personalized treatment algorithms

Scoring (10-Dimension Rubric)

| Dimension | Score | Rationale |
|-----------|-------|-----------|
| Novelty | 8 | Adaptive dosing protocols for tau immunotherapy are in early development; p-tau217 as dynamic biomarker is emerging |
| Mechanistic Rationale | 9 | Strong biological basis linking p-tau217 to treatment response |
| Root-Cause Coverage | 8 | Addresses tau pathology but uses biomarker rather than direct mechanism |
| Delivery Feasibility | 9 | Uses existing anti-tau antibodies; only adds biomarker monitoring |
| Safety Plausibility | 8 | Adaptive dosing could improve safety by reducing unnecessary exposure |
| Combinability | 9 | Highly compatible with other anti-tau, anti-amyloid, or neuroprotective approaches |
| Biomarker Availability | 9 | p-tau217 assays are commercially available and validated |
| De-risking Path | 8 | Clear regulatory pathway using existing antibody frameworks |
| Multi-disease Potential | 7 | Primarily AD-focused; some applicability to primary tauopathies |
| Patient Impact | 8 | Personalized dosing improves outcomes and reduces adverse events |
| Total | 81/100 | Calculated from 10 dimensions |

Implementation Strategy

Phase 1: Baseline Assessment

• Establish baseline p-tau217 levels at screening
• Confirm amyloid and/or tau positivity per inclusion criteria
• Define individual "responder" profile

Phase 2: Initial Treatment

• Standard induction dosing (e.g., loading dose series)
• p-tau217 sampling at weeks 4, 8, 12, 16

Phase 3: Adaptive Titration

• Responder algorithm: If p-tau217 decline >30% from baseline, maintain current dose
• Partial responder: If decline 15-30%, consider dose escalation
• Non-responder: If decline <15%, re-evaluate or add combination therapy

Phase 4: Maintenance

• Ongoing p-tau217 monitoring every 3-6 months
• Dose adjustments based on sustained response or relapse

De-risking Path

Technical De-risking

Clinical De-risking

Commercial De-risking

Risks and Mitigation

Key Risks

• Mitigation: Standardize to single assay for clinical use; develop conversion algorithms

• Mitigation: Set clear minimum/maximum dose boundaries; require sustained elevation for escalation

• Mitigation: Use multiple tau biomarkers (p-tau181, p-tau231) for validation

• Mitigation: Develop less invasive sampling methods; use dried blood spot testing

• Mitigation: Include biomarker validation endpoints in Phase 3 trials

Timeline

| Phase | Duration | Milestones |
|-------|----------|------------|
| Assay Standardization | 6 months | Single-platform validation |
| Phase 2 Trial | 18 months | Biomarker-guided dosing |
| Phase 3 Trial | 24 months | Registrational trial |

Estimated Cost

| Phase | Estimated Cost | Notes |
|-------|-----------------|-------|
| Assay Development | $2-3M | Standardization |
| Phase 2 | $15-20M | Adaptive design |
| Phase 3 | $30-40M | Registration |
| Total | $47-63M | End-to-end |

Key Academic Centers

• University of Gothenburg — Henrik Zetterberg
• Washington University — Randall Bateman
• Mayo Clinic — Michelle Mielke

Potential Partner Companies

• Roche — Elecsys p-tau217
• Eli Lilly — p-tau217 assays
• Quanterix — Simoa platform
• Biogen — AD pipeline

Actionable Next Steps

Lab Experiments

Clinical Protocol Design

Company Partnership Opportunities

• Eli Lilly (semorimenab) — already has tau pipeline
• Biogen/AstraZeneca (gosuranemab) — partnered on tau
• AbbVie — seeking differentiation in crowded space

• Roche Diagnostics — Neurop sekter p-tau217 platform
• Fujirebio — Lumipulse CSF p-tau217
• C2N Diagnostics — PrecivityAD blood test

Grant Targets

• R21 (Exploratory/Developmental): "p-Tau217-guided adaptive anti-tau dosing in early AD" (~=K over 2 years)
• U01 (Phase 2 trial planning): "Adaptive Dosing Platform for Tau Immunotherapy" (~M over 3 years)
• SBIR/STTR (with diagnostic partner): Companion diagnostic development

• BrightFocus Foundation — A2022015N (AD biomarker trials)
• Alzheimer's Association — Part the Cloud (Phase 1/2 clinical trials)
• Michael J. Fox Foundation — therapeutic biomarker studies

• EU Joint Programme — Neurodegenerative Disease Research (JPND)
• UK Dementia Research Institute

Implementation Roadmap

Phase 1: Assay Validation & Algorithm Development (Months 1-18)

| Milestone | Timeline | Cost | Risk |
|-----------|----------|------|------|
| p-Tau217 multi-vendor comparison study | Months 1-9 | $800K | Low |
| Adaptive algorithm ML model development | Months 6-15 | $1.2M | Medium |
| Pre-IND meeting with FDA | Month 12 | $200K | Low |
| IND-enabling pharmacology summary | Months 12-18 | $500K | Low |

Key Risks:

• Assay variability could require additional validation (mitigation: include 3+ vendors)
• Algorithm accuracy may need iteration (mitigation: iterative training with real trial data)

Phase 2: Phase 2 Adaptive Dosing Trial (Months 15-36)

| Milestone | Timeline | Cost | Risk |
|-----------|----------|------|------|
| Site initiation (15-20 sites US/EU) | Months 15-18 | $1.5M | Low |
| Patient enrollment (n=200 adaptive) | Months 18-30 | $6M | Medium |
| Interim analysis (week 48) | Month 30 | $500K | Medium |
| Final analysis (week 96) | Month 36 | $1M | Low |

Key Risks:

• Enrollment could miss targets (mitigation: inclusion of international sites)
• Adaptive algorithm may need adjustment (mitigation: pre-specified adaptation rules)

Phase 3: Phase 3 Registration Trial (Months 30-60)

| Milestone | Timeline | Cost | Risk |
|-----------|----------|------|------|
| Phase 3 protocol finalization | Months 30-33 | $2M | Low |
| Global enrollment (n=800-1000) | Months 33-48 | $25M | Medium |
| Phase 3 readout | Month 56 | $5M | Medium |
| NDA/MAA filing and approval | Months 56-60 | $8M | Low |

Key Risks:

• Phase 2/3 regulatory feedback may require design changes
• Competition from standard-of-care anti-tau antibodies

Total Program Cost: $45-74M over 60 months

Risk-Adjusted Scenarios

| Scenario | Probability | Cost Impact |
|----------|-------------|-------------|
| Best case (accelerated approval) | 15% | $35M |
| Base case | 50% | $55M |
| Slow enrollment + one protocol amendment | 25% | $75M |
| Program pivot (new target) | 10% | +$20M |

Academic Center Recommendations

Decision Gates

| Gate | Criteria | Go/No-Go |
|------|----------|----------|
| Phase 1→2 | Positive assay validation + FDA feedback | Go if assay CV <15% |
| Phase 2→3 | Week 48 p-Tau217 correlation with cognition | Go if r > 0.4, p < 0.01 |
| Registration | Phase 3 interim shows significance | Go if p < 0.025 |

Next Steps

Immediate Actions (0-3 months)

Near-term Milestones (3-12 months)

Research Gaps to Address

• Establish p-Tau217 cutoff thresholds for treatment response (not just diagnosis)
• Validate correlation between plasma p-Tau217 and CSF p-Tau217 in treatment-naive subjects
• Assess assay performance in diverse ethnic populations

Collaboration Opportunities

• Academic: Join DIAN-TU consortium for adaptive trial design expertise
• Pharma: Partner with tau immunotherapy companies ( Lilly, Roche) for combination trial potential
• Diagnostic: Work with ALZpath and Quanterix on assay standardization

See Also

• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)

External Links

• [PubMed](https://pubmed.ncbi.nlm.nih.gov/)
• [KEGG Pathways](https://www.genome.jp/kegg/pathway.html)

Cross-Links

• [Tau Protein](/proteins/tau)
• [Biomarkers for Neurodegeneration](/mechanisms/neurodegeneration-biomarkers)
• [p-Tau217 Biomarker](/mechanisms/ptau217-biomarker)
• [Alzheimer's Disease](/diseases/alzheimers-disease)

Rubric Score

| Dimension | Score | Rationale |
|-----------|-------|-----------|
| Novelty | 7/10/10 | p-tau217 as biomarker is breakthrough; adaptive dosing is innovative |
| Mechanistic Rationale | 6/10/10 | Uses biomarker for treatment guidance; addresses pharmacokinetics, not pathology |
| Addresses Root Cause | 6/10/10 | Optimizes drug delivery; indirect effect on disease modification |
| Delivery Feasibility | 7/10/10 | Same as standard dosing; biomarker drives timing |
| Safety Plausibility | 7/10/10 | Enhanced safety monitoring; biomarker-guided dose adjustment |
| Combinability | 7/10/10 | Compatible with any disease-modifying therapy |
| Biomarker Availability | 9/10/10 | p-tau217 is highly validated; accessible via blood test |
| De-risking Path | 8/10/10 | Platform approach; can be applied to multiple drugs |
| Multi-disease Potential | 7/10/10 | Broad applicability across AD therapeutics |
| Patient Impact | 8/10/10 | Could significantly improve therapeutic outcomes and reduce adverse events |
| Total | 72/100 | |

References